GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Forward PE Ratio

NLS Pharmaceutics (NLS Pharmaceutics) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Forward PE Ratio?

NLS Pharmaceutics's Forward PE Ratio for today is 0.00.

NLS Pharmaceutics's PE Ratio without NRI for today is 0.00.

NLS Pharmaceutics's PE Ratio for today is 0.00.


NLS Pharmaceutics Forward PE Ratio Historical Data

The historical data trend for NLS Pharmaceutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Forward PE Ratio Chart

NLS Pharmaceutics Annual Data
Trend
Forward PE Ratio

NLS Pharmaceutics Semi-Annual Data
Forward PE Ratio

Competitive Comparison of NLS Pharmaceutics's Forward PE Ratio

For the Biotechnology subindustry, NLS Pharmaceutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NLS Pharmaceutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Forward PE Ratio falls into.



NLS Pharmaceutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


NLS Pharmaceutics  (NAS:NLSP) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


NLS Pharmaceutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.